Related Experiment Video
Updated: Jun 2, 2026
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Mouse relapse model of Clostridium difficile infection.
Xingmin Sun1, Haiying Wang, Yongrong Zhang
1Tufts Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536, USA.
Infection and Immunity
|May 18, 2011
Summary
A new mouse model for recurrent Clostridium difficile infection (CDI) was developed. This model showed that neutralizing antibodies against C. difficile toxins TcdA and TcdB effectively prevented CDI relapse, unlike vancomycin.
Area of Science:
- Microbiology
- Immunology
- Infectious Diseases
Background:
- Clostridium difficile infection (CDI) causes antibiotic-associated diarrhea and colitis.
- Recurrent CDI affects over 20% of patients and poses a significant clinical challenge.
- Existing animal models do not adequately replicate CDI relapse.
Purpose of the Study:
- To establish a conventional mouse model for studying recurrent CDI (relapse).
- To investigate host immune responses and test therapeutic strategies for CDI recurrence.
Main Methods:
- Established a mouse model by inducing primary CDI, followed by antibiotic treatment and re-exposure.
- Assessed antibody responses to C. difficile toxins (TcdA, TcdB).
- Evaluated vancomycin and neutralizing polysera (anti-TcdA and anti-TcdB) for efficacy against relapse.
Main Results:
- The primary CDI episode generated minimal protective antibodies and spore shedding.
- Antibiotic treatment induced CDI relapse; re-exposure exacerbated disease.
- Immunosuppression led to more severe recurrent CDI.
- Vancomycin only delayed recurrence, while anti-TcdA/TcdB polysera prevented relapse.
Conclusions:
- A reliable mouse model for CDI relapse has been developed.
- The model facilitates research into CDI pathogenesis and host immunity.
- Neutralizing antibodies against TcdA and TcdB are crucial for preventing CDI relapse, offering a promising therapeutic target.
